167 related articles for article (PubMed ID: 20103669)
1. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma.
McKibbin T; Panetta JC; Fouladi M; Gajjar A; Bai F; Okcu MF; Stewart CF
Clin Cancer Res; 2010 Feb; 16(3):1049-57. PubMed ID: 20103669
[TBL] [Abstract][Full Text] [Related]
2. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.
Fouladi M; Chintagumpala M; Ashley D; Kellie S; Gururangan S; Hassall T; Gronewold L; Stewart CF; Wallace D; Broniscer A; Hale GA; Kasow KA; Merchant TE; Morris B; Krasin M; Kun LE; Boyett JM; Gajjar A
J Clin Oncol; 2008 Aug; 26(22):3749-55. PubMed ID: 18669462
[TBL] [Abstract][Full Text] [Related]
3. New liquid chromatographic assay with electrochemical detection for the measurement of amifostine and WR1065.
Bai F; Kirstein MN; Hanna SK; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Jun; 772(2):257-65. PubMed ID: 12007770
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma.
Gurney JG; Bass JK; Onar-Thomas A; Huang J; Chintagumpala M; Bouffet E; Hassall T; Gururangan S; Heath JA; Kellie S; Cohn R; Fisher MJ; Panandiker AP; Merchant TE; Srinivasan A; Wetmore C; Qaddoumi I; Stewart CF; Armstrong GT; Broniscer A; Gajjar A
Neuro Oncol; 2014 Jun; 16(6):848-55. PubMed ID: 24414535
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
Fouladi M; Stempak D; Gammon J; Klein J; Grant R; Greenberg ML; Koren G; Baruchel S
Cancer; 2001 Aug; 92(4):914-23. PubMed ID: 11550166
[TBL] [Abstract][Full Text] [Related]
6. In vitro protection from cisplatin-induced neurotoxicity by amifostine and its metabolite WR1065.
Verstappen CC; Geldof AA; Postma TJ; Heimans JJ
J Neurooncol; 1999 Aug; 44(1):1-5. PubMed ID: 10582662
[TBL] [Abstract][Full Text] [Related]
7. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Fisher MJ; Lange BJ; Needle MN; Janss AJ; Shu HK; Adamson PC; Phillips PC
Pediatr Blood Cancer; 2004 Dec; 43(7):780-4. PubMed ID: 15390300
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Korst AE; Gall HE; Vermorken JB; van der Vijgh WJ
Cancer Chemother Pharmacol; 1996; 39(1-2):162-6. PubMed ID: 8995515
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of amifostine and its metabolites in patients.
Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma.
Shi ZY; Liu YO; Gu HY; Xu XQ; Yan C; Yang XY; Yan D
Biopharm Drug Dispos; 2020 Mar; 41(3):101-110. PubMed ID: 32017134
[TBL] [Abstract][Full Text] [Related]
11. Amifostine protects against cisplatin-induced nephrotoxicity in a child with medulloblastoma.
Hayek M; Srinivasan A
Pediatr Hematol Oncol; 2003; 20(3):253-6. PubMed ID: 12637222
[No Abstract] [Full Text] [Related]
12. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
13. Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma.
Zamboni WC; Gajjar AJ; Heideman RL; Beijnen JH; Rosing H; Houghton PJ; Stewart CF
Clin Cancer Res; 1998 Mar; 4(3):783-9. PubMed ID: 9533548
[TBL] [Abstract][Full Text] [Related]
14. No evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
Zackrisson AL; Malmström H; Peterson C
Eur J Clin Pharmacol; 2002 May; 58(2):103-8. PubMed ID: 12012141
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity after intensity-modulated radiation therapy and cisplatin-based chemotherapy in children with medulloblastoma.
Paulino AC; Lobo M; Teh BS; Okcu MF; South M; Butler EB; Su J; Chintagumpala M
Int J Radiat Oncol Biol Phys; 2010 Dec; 78(5):1445-50. PubMed ID: 20231075
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
[TBL] [Abstract][Full Text] [Related]
17. Administration of Ethyol (amifostine) to a child with medulloblastoma to ameliorate hematological toxicity of high dose carboplatin.
Borsi JD; Csaki C; Ferencz T; Oster W
Anticancer Drugs; 1996 Jan; 7(1):121-6. PubMed ID: 8742109
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by repeated administration of the free thiol form of amifostine.
Murley JS; Nantajit D; Baker KL; Kataoka Y; Li JJ; Grdina DJ
Radiat Res; 2008 May; 169(5):495-505. PubMed ID: 18439041
[TBL] [Abstract][Full Text] [Related]
19. WR-2721 (amifostine) infusion in patients with Ewing's sarcoma receiving ifosfamide and cyclophosphamide with mesna: drug and thiol levels in plasma and blood cells, a Pediatric Oncology Group study.
Souid AK; Fahey RC; Dubowy RL; Newton GL; Bernstein ML
Cancer Chemother Pharmacol; 1999; 44(6):498-504. PubMed ID: 10550571
[TBL] [Abstract][Full Text] [Related]
20. Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.
Freeman BB; Iacono LC; Panetta JC; Gajjar A; Stewart CF
Neuro Oncol; 2006 Apr; 8(2):89-95. PubMed ID: 16461424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
